Regulatory Processes for Rare Disease Drugs in the United States and European Union: Flexibilities and Collaborative Opportunities
- PMID: 39585949
- Bookshelf ID: NBK609392
- DOI: 10.17226/27968
Regulatory Processes for Rare Disease Drugs in the United States and European Union: Flexibilities and Collaborative Opportunities
Excerpt
Rare diseases, such as sickle cell disease and thalassemia, affect up to 30 million people in the United States and at least 300 million across the globe. Congress called on the U.S. Food and Drug Administration (FDA) to sponsor a National Academies study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. The resulting report provides recommendations for enhancing and promoting rare disease drug development by improving engagement with people affected by a rare disease, advancing regulatory science, and fostering collaboration between FDA and the European Medicines Agency.
Copyright 2024 by the National Academy of Sciences. All rights reserved.
Sections
- The National Academies of SCIENCES • ENGINEERING • MEDICINE
- COMMITTEE ON PROCESSES TO EVALUATE THE SAFETY AND EFFICACY OF DRUGS FOR RARE DISEASES OR CONDITIONS IN THE UNITED STATES AND THE EUROPEAN UNION
- Reviewers
- Acknowledgments
- Preface
- Acronyms and Abbreviations
- Summary
- 1. Introduction
- 2. FDA Flexibilities, Authorities, and Mechanisms
- 3. EMA Flexibilities, Authorities, and Mechanisms
- 4. Alternative and Confirmatory Data
- 5. FDA and EMA Collaboration
- Appendix A. Biographical Sketches of Committee Members and Staff
- Appendix B. Disclosures of Unavoidable Conflicts of Interest
- Appendix C. Public Meeting Agendas
- Appendix D. Centre for Innovation in Regulatory Science Data Analysis Methodology
- Appendix E. Qualitative Interview Summary and Methodology
- Appendix F. Non-Exhaustive List of Patient Focused Drug Development Meetings and Patient Listening Sessions for Rare Diseases Between 2013 and 2023
- Appendix G. List of Orphan Approvals by FDA or EMA Between 2018 and 2022
- Appendix H. Select Examples of Rare Disease Drug Products
- Appendix I. FDA and EMA Resources, Policies, and Programs Relevant for Drug Development for Rare Diseases and Conditions
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
